Pharmaceutical

Image

Global Polycystic Kidney Disease (PKD) Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Sep 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Polycystic Kidney Disease (PKD) Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR - % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 0.49 Billion
Diagram Market Size (Forecast Year) USD 0.77 Billion
Diagram CAGR %

Global Polycystic Kidney Disease (PKD) Market, By Type (Autosomal Dominant Polycystic Kidney Disease, Autosomal Recessive Polycystic Kidney Disease, Others), Treatment (Medication, Surgery, Others), Diagnosis (Ultrasound, CT Scan, MRI Scan), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.

Polycystic Kidney Disease (PKD) Market Analysis and Size

In recent years, the global polycystic kidney disease (PKD) market is anticipated to grow rapidly during the forecast period of 2023 to 2030, owing to the rising prevalence of kidney disorders. Polycystic kidney disease is caused by genetic abnormalities. In the majority of cases, the disorder is passed down to the children by their parents. As a result, you are born with PKD. However, genes can mutate or change at any time.                         

Data Bridge Market Research analyzes that the global polycystic kidney disease (PKD) market which was USD 0.49 billion in 2022, is expected to reach USD 0.77 billion by 2030, and is expected to undergo a CAGR of 5.8% during the forecast period 2023 to 2030. “Autosomal Dominant Polycystic Kidney Disease” dominates the type segment of the global polycystic kidney disease (PKD) market owing to the increasing prevalence of thalassemia. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.     

Polycystic Kidney Disease (PKD) Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Year

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

 Type (Autosomal Dominant Polycystic Kidney Disease, Autosomal Recessive Polycystic Kidney Disease, Others), Treatment (Medication, Surgery, Others), Diagnosis (Ultrasound, CT Scan, MRI Scan), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)

Countries Covered

U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America

Market Players Covered

Johnson & Johnson Services Inc. (U.S.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U S.), GSK plc (U.K.), AbbVie Inc. (U.S.), Novartis AG (Switzerland), Taro Pharmaceutical Industries Ltd. (U.S.), Otsuka Pharmaceutical Co., Ltd. (Japan), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), CorePharma LLC (U.S.), Hikma Pharmaceuticals Plc (U.K.), Kadmon Holdings Inc. (U.S.), Reata Pharmaceuticals Inc. (U.S.), Merck & Co., Inc. (U.S.), AstraZeneca (UK)    

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches  

Market Definition

The genetic ailment polycystic kidney disease (PKD) causes cysts to form in the kidneys, causing them to malfunction. High blood pressure and renal failure are two health problems. PKD is a kind of chronic kidney disease that is very dangerous. Cysts can enlarge the kidneys, making it difficult for them to filter waste from the blood.

Global Polycystic Kidney Disease (PKD) Market Dynamics

Drivers

  • Increasing Incidences of Kidney Failure

The global polycystic kidney disease (PKD) market is driven by an increase in incidences of renal failure or dialysis. Polycystic kidney disease can be caused by a number of factors, including a family history of kidney problems, a rare genetic mutation, kidney failure, or people on dialysis, all of which will raise the global polycystic kidney disease (PKD) market.

  •  Increasing Investment for Healthcare Infrastructure

Another significant factor influencing the growth rate of global polycystic kidney disease (PKD) market is the rising healthcare expenditure which helps in improving its infrastructure. Furthermore, rising initiatives by public and private organizations to spread awareness will expand the global polycystic kidney disease (PKD) market. Additionally, high disposable income and rising demand for advanced treatment and innovative solutions will result in the expansion of global ​​​​​​​polycystic kidney disease (PKD) market. Along with this, favourable government policies and rising awareness about genetic diseases among people will enhance the growth rate of the market.

Opportunity

  • Increase in the number of Research and Development Activities

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the global polycystic kidney disease (PKD) market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the global polycystic kidney disease (PKD) market growth during the forecast period.

Restraint/Challenge

  • High Cost associated with the Treatment of Polycystic Kidney Disease (PKD)

On the other hand, the high cost associated with the treatment of polycystic kidney disease (PKD) will obstruct the growth rate of global market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the global polycystic kidney disease (PKD) market.  In addition, impact of COVID-19 on supply chain and the dearth of awareness will act as restrain and further impede the growth rate of market during the forecast period of 2023 to 2030.

This global polycystic kidney disease (PKD) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. To gain more info on the surgical microscopes market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.    

Recent Development

  • In May 2023, a new Monash biotech business won money to slow the growth of polycystic kidney disease. Cystence Bio, a new Monash biotech business, has secured funding to accelerate research into novel therapies for polycystic kidney disease (PKD), a family of hereditary illnesses characterized by the formation of many large cysts in the kidneys

Global Polycystic Kidney Disease (Pkd) Market Scope  

The global polycystic kidney disease (PKD) market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.   

Type

  • Autosomal Dominant Polycystic Kidney Disease
  • Autosomal Recessive Polycystic Kidney Disease
  • Others

Treatment

  • Medication
  • Surgery
  • Others

Diagnosis

  • Ultrasound
  • CT Scan
  • MRI Scan

Route Of Administration

  • Oral
  • Parenteral
  • Others

End-Users

  • Hospital
  • Speciality Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Global Polycystic Kidney Disease (PKD) Market Regional Analysis/Insights  

The global polycystic kidney disease (PKD) market is analyzed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the global polycystic kidney disease (PKD) market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.    

North America dominates the global polycystic kidney disease (PKD) market because of the increasing healthcare initiatives, the strong presence of major players in the market, increasing cases of kidney diseases and rising number of research activities in this region.

Asia-Pacific is expected to witness significant growth in the global polycystic kidney (PKD) market, during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global polycystic kidney disease (PKD) market also provides you with detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global polycystic kidney disease (PKD) market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global polycystic kidney disease (PKD) market. The data is available for the historic period 2015-2020.      

Competitive Landscape and Global Polycystic Kidney Disease (PKD) Market Share Analysis 

The global polycystic kidney disease (PKD) market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.    

Some of the major players operating in the global polycystic kidney disease (PKD) market are:   

  • Johnson & Johnson Services Inc. (U.S.)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GSK plc (U.K.)
  • AbbVie Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Eli Lilly and Company (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Merck & Co., Inc. (U.S.)
  • Taro Pharmaceutical Industries Ltd. (U.S.)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • CorePharma LLC (U.S.)
  • Hikma Pharmaceuticals Plc (U.K.)
  • Kadmon Holdings Inc. (U.S.)
  • Reata Pharmaceuticals Inc. (U.S.)
  • AstraZeneca (U.K.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The global polycystic kidney disease (PKD) market value was USD 0.49 billion in 2022.
The global polycystic kidney disease (PKD) market is projected to grow at a CAGR of 5.8% during the forecast period of 2023-2030.
Increasing Incidences of Kidney Failure & Increasing Investment for Healthcare Infrastructure are the growth drivers of the polycystic kidney disease (PKD) market.
Type, treatment, diagnosis, route of administration, end-users and distribution channel are the factors on which the polycystic kidney disease (PKD) market research is based.
Major companies in the polycystic kidney disease (PKD) market are Johnson & Johnson Services Inc. (U.S.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U S.), GSK plc (U.K.), AbbVie Inc. (U.S.), Novartis AG (Switzerland), Taro Pharmaceutical Industries Ltd. (U.S.), Otsuka Pharmaceutical Co., Ltd. (Japan), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), CorePharma LLC (U.S.), Hikma Pharmaceuticals Plc (U.K.), Kadmon Holdings Inc. (U.S.), Reata Pharmaceuticals Inc. (U.S.), Merck & Co., Inc. (U.S.), AstraZeneca (UK).
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials